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Epidemiological Monitoring of HIV and AIDS) and presents information provided by the national 
coordinators for the surveillance of HIV/AIDS in the WHO European Region. 
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Foreword 
 
 
 
 
This report, the last issue of HIV/AIDS Surveillance in Europe, turns an important page for the 
EuroHIV project since, from January 2008, the coordination of the surveillance of HIV/AIDS in 
Europe will be carried out jointly by the European Centre for Disease Prevention and Control 
(ECDC) in Stockholm and the WHO Regional Office for Europe (WHO Euro) in Copenhagen.  
 
The first report on the surveillance of AIDS in Europe, issued in April 1984 by the forerunner of 
EuroHIV – the WHO Collaborating Centre on AIDS, presented information on AIDS cases 
reported in 11 countries. The number of countries increased progressively in subsequent years 
to reach 53 in 2006 and a wide range of topics have been covered including the estimation of 
AIDS under-reporting, mortality data, analysis of reporting delays, European AIDS surveillance  
case definition, estimates of HIV cumulative incidence and prevalence, HIV testing, HIV 
prevalence in specific populations. Results from studies included in the European HIV 
Prevalence Database have been presented regularly since 1991. The European HIV case 
reporting system was set up in 1999 with most countries participating.  
 
In this last EuroHIV report, we focus on the prevalence of HIV in blood donations and present 
an overview of recent HIV prevalence studies performed among injecting drug users in the 
WHO European Region. We hope that this will contribute to a better understanding of the HIV 
epidemic in Europe. 
 
Finally, we would like to acknowledge the outstanding work of Jean-Baptist Brunet who, with the 
support of many other devoted people, established and ensured the continuation of the EuroHIV 
project here in France for over 20 years.  We owe a debt of gratitude to past and present 
members of the EuroHIV Steering Group who were instrumental in directing our scientific 
priorities, to the national correspondents who participated actively in the European HIV network 
and to the personnel of Institut de Veille Sanitaire (InVS) and WHO Euro, who constantly 
supported EuroHIV over the years.  
 
 
 
 
 
 
 
 
 
Giedrius Likatavičius 
on behalf of the EuroHIV team 
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1. Prevalence of HIV infection 
among injecting drug users 
 
 
Key points  
• Very high levels (>50%) of HIV 
prevalence were found in 
seroprevalence studies in cities of 
many Eastern countries, although sub-
national HIV prevalence varied 
substantially; 
• Much lower levels of epidemic were 
reported in the West, mainly confined 
to Portugal, Spain and Italy and in the 
Centre, mainly attributed to Poland. 
 
Recommendations for public health  
• Target IDU in HIV testing campaigns;   
• Scale up preventive interventions 
known to be effective among IDU;  
• Target measures to prevent increasing 
sexual HIV transmission among 
partners of IDU.  
 
Recommendations for surveillance 
• Include the collection of behavioural 
data in HIV surveillance of IDU;  
• Monitor HIV testing among IDU; 
• Consider the usefulness of 
implementing HIV incidence testing in 
order to assess recent infections for 
evaluation of interventions and more 
appropriate targeting of actions.  
 
 
1.1 Introduction 
 
This section presents the following data 
reported to the end of 2006 for the 53 
countries of the WHO European Region: 
• Newly diagnosed HIV cases reported 
among IDU; 
• HIV prevalence studies among IDU.  
 
 
1.2 Reporting of HIV cases among 
IDU  
 
By the end of 2006, 50 of the 53 countries 
in the WHO European Region had 
reported national HIV data on newly 
diagnosed HIV cases which were 
presented in the EuroHIV report  No. 75 
[1]. The three countries not reporting 
national HIV data were Italy, Monaco and 
Spain, although data from a number of 
Italian and Spanish regions have been 
included.   
 
In 2006, a total of 86,912 newly diagnosed 
HIV cases were reported from 50 
countries in the WHO European Region. 
Of these, 24,102 cases of HIV were 
reported among IDU (Annex 1.1). The 
status of the HIV epidemic among IDU 
varies according to the region and country.  
 
Figure 1.1: Predominant route of 
transmission of newly diagnosed HIV 
cases in WHO European Region, 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predominant transmission group
MSM
Heterosexual
Injecting drug use
Data unavailable
A major epidemic among IDU occurred in  
the East during the last decade. Of the 
59,866 newly diagnosed cases reported in 
2006 (a rate of 210.8 per million 
population), 22,376 (62%) were among 
IDU (data on transmission group   missing 
for 23,936 cases). IDU represented the 
predominant transmission group in 11 of 
the 14 countries that reported route of 
transmission, (Figure 1.1). A peak in new 
HIV diagnoses reported among IDU 
occurred in 2001 (100,578 cases) (Figure 
1.2), of which the majority (95,253 cases, 
95%) were reported from the Russian 
Federation (88%) and Ukraine (7%). Since 
then, the number of cases among IDU has 
declined, most notably in the Russian 
Federation (from 48,231 in 2001 to 11,161 
in 2006) and Latvia (from 665 to 108). 
However, since 2001, large increases 
have been observed in the number of HIV 
cases reported among IDU in eight 
countries: Azerbaijan, Georgia, 
Kazakhstan, Kyrgyzstan, Moldova, 
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Tajikistan, Ukraine and Uzbekistan (Annex 
1.1) [1] .  
 
In the Centre, the HIV epidemic has 
remained at a low level, with 1,805 newly 
diagnosed cases reported in 2006 (a rate 
of 9.4 per million population), of which 177 
(17%) were among IDU (data on 
transmission group missing for 711 
cases). Since 1999, the number of reports 
of new diagnoses among IDU has 
declined from 295 to 177 in 2006. 
 
Figure 1.2: HIV infections newly diagnosed 
among injecting drug users, by geographic 
area,  WHO European Region, 1999-2006  
 
 
 
 
 
 
 
 
 
 
 
 
 
In the West the HIV epidemic among IDU 
is much older and peaked in mid 1980s 
[2]. In 2006, 25,241 newly diagnosed 
cases of HIV infection were reported (a 
rate of 82.5 per million population) of 
which 1,549 (8%) were among IDU (data 
on transmission group missing for 5,332 
cases). Since 1999, in 13 countries with 
consistent HIV reporting systems, the 
number of new HIV diagnoses reported 
among IDU has declined by 12.5% (from 
710 in 1999 to 643 in 2006). However, 
these trends do not include data for Italy, 
Spain and Portugal, where extensive 
epidemics among IDU have been reported 
in the past. Nonetheless, recent national 
data from Portugal and regional data from 
both Italy and Spain do corroborate this 
decline in HIV diagnoses among IDU 
(Annex 1.1). 
 
1.3 HIV prevalence studies  
 
Information on HIV prevalence studies 
conducted among injecting drug users has 
been collected since 1992 and published 
in four reports, the most recent being  
report No. 70 which was  published in 
2004 and covered the period 1998 to 2003 
[3]. The data presented in this report cover 
the period 2001 to 2006.  
 
Information on HIV prevalence studies 
among IDU included in the European HIV 
Prevalence Database (see Technical note) 
have been supplemented by data obtained 
from the European Monitoring Centre for 
Drugs and Drug Addiction [4]. For the 
period 2001-2006, data from over 80 
studies or data collection systems in 40 
countries, together with details of the 
tested populations, surveillance methods 
used and references [4-42] are presented 
in Annexes 1.2-1.4. The three most 
commonly reported types of studies are: 
0
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• Seroprevalence studies (SP): based 
either on testing of serum or saliva. In 
some studies, these data are based on 
unlinked anonymous testing (SP-UAT), 
which have a reduced sampling bias 
compared to diagnostic testing results.    
• Diagnostic testing (DT): refers here to 
the systematic reporting of results of all 
testing carried out with the primary 
objective of providing individuals with 
their serostatus. HIV testing may have 
been offered by the clinician, either as 
part of routine testing or in the context of 
clinical care, or it may have been 
initiated by the individuals themselves. 
Results from diagnostic testing are the 
most difficult to interpret as they depend 
on a variety of factors, including HIV 
testing patterns and policies, and are 
subject to strong participation biases, 
which can increase over time as persons 
already known to be HIV-positive are 
excluded. Data with national coverage 
are frequently, though not always, the 
results from diagnostic testing. 
• Self-reported studies (SR):  HIV status 
is reported by the individual patient. The 
validity of a self-reported HIV status is 
less than that obtained by the testing of 
a biological sample. Nonetheless, self-
reported status is more easily employed 
in the field as it avoids the difficulties of 
collecting biological samples in a 
community setting. 
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It is not only the type of study 
methodology, but also the setting of the 
study that can have a major impact on the 
interpretation of the results and hinder 
comparisons between different studies. 
For example, the prevalence of HIV will 
vary depending on whether the sample of 
IDU is recruited from specialised centres 
providing treatment for drug addiction 
(where patients may have a longer history 
of IDU and thus a higher prevalence) or 
from outreach programmes (where 
individuals may have a shorter history of 
IDU and thus a lower prevalence). Some 
studies include not only current or former 
IDU but also drug users who have never 
injected and are thus less at risk for HIV 
infection. Furthermore, in three studies, 
HIV prevalence was estimated by testing 
used syringes and, in three other studies, 
HIV prevalence was determined from 
autopsies of drug related deaths.   
 
 
1.3.1 HIV prevalence in the West 
 
For the period 2001-2006, data were 
available from 15 of the 23 countries with 
geographical coverage ranging from cities 
to regional or national level (countries 
provided the data only for specific sub-
populations not included, see paragraph 
1.4). Data were most often obtained from 
drug treatment centres and rehabilitation 
facilities. In addition, specific prevalence 
studies have been conducted in needle 
exchange facilities (Annex 1.2). Data from 
other studies were obtained in both 
treatment and community settings. 
 
In three countries, HIV prevalence levels 
greater than 20% have been found in at 
least one city or region: 
• Spain: diagnostic testing data from IDU 
starting treatment in Catalonia 
provided the highest reported HIV 
prevalence in western Europe (38% in 
2001). Although only about 17% of IDU 
tested were female, HIV prevalence 
was consistently higher among female 
than male IDU (41% versus 37% in 
2001);  
• Italy: HIV prevalence among drug 
users attending treatment centres 
nationally was 14% in 2005 and varied 
from 3% in Campania to 28% in 
Sardinia; 
• France: in three studies on drug use, 
self-reported HIV prevalence was 14-
24% in 2001-2003 and in a UAT sero-
prevalence study in 2004 levels varied 
from 1% in Lille to 32% in Marseille 
(national average 11%).   
 
HIV prevalence of between 10%-20% 
were reported in three other countries: 
• Ireland: in a part of greater Dublin 
sero-prevalence study of IDU in 
treatment reported a prevalence of 
11% in 2002;  
• Portugal: national diagnostic testing 
data collected annually from drug 
users starting treatment revealed a 
high prevalence of 15% in 2003;  
• Germany: in a study conducted 
annually between 2002 and 2004 
among IDU recruited from the streets 
of Frankfurt, the highest prevalence of 
self-reported HIV status was 17% in 
2003. 
 
In the remaining countries, HIV prevalence 
reported among IDU was generally low 
(<5%), although local HIV prevalence of 
between 5 and 10% were reported in four 
countries:  
• Belgium: in 2004, the self-reported 
prevalence of HIV among IDU 
recruited from drug treatment centres 
in the French-speaking community was 
9% in 2004 and the sero-prevalence of 
HIV was 7% among drug users 
recruited from drug treatment centres 
and needle exchange programmes in 
Antwerp in 2005;   
• Luxembourg: a self-reported HIV 
prevalence of 5% among drug users 
recruited from a variety of settings in 
2005;  
• Netherlands: an HIV prevalence of 
10% in a UAT study conducted in 
Rotterdam among IDU recruited from 
the street and drug treatment centres 
in 2002;  
• Norway: a prevalence of 6% in a study 
among IDU starting drug treatment in 
the eastern region of Norway in 2005.  
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Data for young IDU (<25 years) or for 
recent injectors (<2 years) were available 
for three countries and show levels 
consistently lower than those for IDU who 
are older or who have injected for more 
than 2 years.  Nevertheless, among young 
IDU (<25 years of age) in Catalonia the 
reported prevalence of HIV was 13% in 
2001 and in Spain (excluding Madrid and 
Rioja), the prevalence among new IDU 
(injecting history of <2 years) was 18% in 
2002 (Annex 1.2). 
 
1.3.2 HIV prevalence in the Centre 
 
Data were available from 20 studies 
(studies on specific sub-populations not 
included, see paragraph 1.4) or systems in 
nine of the 15 countries of the Centre. 
Among these, seven systems in five 
countries (Croatia, Czech Republic, 
Hungary, Poland, Slovenia) have national 
coverage, while seroprevalence studies 
(HIV status determined by either testing 
serum or saliva) at city or regional level 
have been conducted in seven countries 
(Bosnia and Herzegovina, Bulgaria, the 
Czech Republic, Hungary, Poland, 
Slovenia and Slovakia) (Annex 1.3). As in 
the West, drug treatment centres are the 
main source of data, but data have also 
been collected through harm reduction 
and outreach programmes, hospitals and 
clinics, prisons and voluntary counselling 
and testing sites. 
 
Reported prevalence levels in diagnostic 
studies remained below 1% in all countries 
except Croatia (1.3% in 2002), Serbia 
(1.2% in 2002) and in Poland, where a 
maximum of 9% was reported nationally 
among IDU seeking treatment in 2001, 
and a prevalence of 36% was reported in 
2002 among IDU at drug treatment 
centres in the Gdansk region.   
 
1.3.3 HIV prevalence in the East 
 
Data were available from 36 studies or 
systems in 14 of the 15 countries (studies 
on specific sub-populations not included, 
see paragraph  1.4) of the East. Most 
countries collected the results of 
diagnostic testing nationally, with most 
data coming from drug treatment centres, 
hospitals or voluntary counselling and 
testing sites. Over the past five years 
however, there has been a marked 
increase in the number of specific sero-
prevalence studies in the East, usually 
conducted at local level in the context of 
harm reduction or street outreach 
programmes.  
 
National data were reported from ten of 
the 15 countries in eastern Europe, and 
the highest HIV prevalence was reported 
in Georgia (22%) in 2001, although data 
were collected not only from drug 
treatment facilities but also prisons. HIV 
prevalence levels in the range of 10-20% 
for at least one year in the period 2001-
2006 were reported by four countries 
(Belarus, Estonia, Latvia and Ukraine) 
(Table 1.1, Annex 1.4). In the remaining 
four countries (Azerbaijan, Lithuania, 
Moldova and the Russian Federation), 
reported prevalence did not exceed 5%, 
except in Armenia (7%) in 2002 and the 
Russian Federation (6%) in 2001. 
 
Table 1.1: Highest reported HIV 
prevalence among IDU from national 
diagnostic testing (DT) studies in eastern 
Europe, 2001-2006  
 
Country Testing Site Year  % 
Armenia  Health services   2002 7.1
Azerbaijan Health services 2006 2.2
Belarus Health services 2006 16.7
Estonia  Health services, 
NEP 2001 13.0
Georgia  Health, justice  
services, NEP  2001 22.2
Latvia  Health and justice 
services 2002 14.6
Lithuania  Health services,  
NEP  2005 3.5
Moldova  Health services 2001 3.6
Russian Fed. NS 2001 6.1
Ukraine  NS 2006 16.5
NEP -  needle exchange programme; NS – non specified. 
 
Trends in reported HIV prevalence have 
decreased since 2001 in four countries 
(Figure 1.3):  
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• Russian Federation: from 6% in 2001 
to 2% in 2006 
• Estonia: from 13% in 2001 to 6% in 
2002,  
• Georgia: from 22% in 2001 to 7% in 
2002, 
• Moldova: from 4% in 2001 to 2.% in 
2006.  
 
Figure 1.3: Decreasing HIV prevalence 
from national diagnostic testing studies in 
the East  
 
 
 
 
 
 
 
 
 
 
 
In contrast, an increase in HIV prevalence 
was reported in two countries (Figure 1.4): 
• Belarus: from 3% in 2001 to 17% in 
2006, 
• Ukraine from 11% in 2001 to 17% 
in 2006.   
 
No clear trend was seen in Armenia, 
Azerbaijan and Lithuania. 
 
Figure 1.4: Increasing HIV prevalence 
from national diagnostic studies in the 
East, 2001-2006 
 
 
 
 
 
 
 
 
 
 
 
 
Large national studies can sometimes 
mask the true situation in the regions or 
cities. At sub-national level in many cities 
and regions in eastern Europe, very high 
prevalences of HIV have been reported, 
and local HIV prevalence of >50% have 
been observed (Figure 1.5): 
• Estonia: the highest prevalence of 90% 
HIV+ in a small sample of high-risk 
behaviour IDU in a needle exchange 
programme was reported in Kohtla-
Jarve in 2005. In the capital, Tallinn, 
HIV prevalence was 54%.   
• Ukraine: studies conducted among 
IDU participating in harm reduction and 
outreach programmes since 2001 
found prevalence levels of >50% in 
Poltava, Odessa, Simferopol and 
Nikolaiev.  
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• Russian Federation: 56% of 418 IDU 
tested in community settings in 
Togliatti in 2001 and 47% of 412 IDU 
in Saint Petersburg in 2006 were HIV-
positive.  
• Belarus: in 2006 the HIV prevalence 
among IDU in harm reduction 
programmes in the city of Zlobin was 
52%. 
 
Figure 1.5: HIV prevalence >50% in 
selected cities in the East, 2001-2006  
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Levels of HIV prevalence between 10-30% 
were found in:  
• Moldova: a prevalence of 22% was 
reported in five cities in Moldova, 
which contrasts strongly with levels of 
<5% found in national diagnostic 
testing.   
• Latvia: in 2002-2005, an HIV 
prevalence of 22% was reported 
among successive samples of around 
200-350 IDU in harm reduction 
programmes in and around Riga.   
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• Azerbaijan:  in 2003, prevalence levels 
of 13-20% were reported from two 
cities (Baku, Lenkoran)  
• Tajikistan: in 2006 levels of 24% were 
found in Dushanbe and 23% in 
Khujand. 
 
Figure 1.6: HIV prevalence  in selected 
cities, in the East, 2003-2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Large differences of HIV prevalence 
between cities and/or regions within a 
country may suggest localised HIV spread 
(Figure 1.6). For example, in the Russian 
Federation, wide variations in HIV 
prevalence between different cities have 
been reported in one study [40], ranging 
from 3% in Volgograd to 14% in Moscow. 
These wide variations between cities and 
regions indicate the possibility of local HIV 
outbreaks. In contrast, in Ukraine, in 10 
cities where HIV prevalence was 
assessed, levels were higher than 20% in 
2004-2006 in all except Makeevka (Annex 
1.4), which suggests a widely spread HIV 
epidemic, reaching high levels in many 
cities and regions. 
 
Two studies reported HIV prevalence 
separately for young people: in Latvia and 
the Russian Federation. In Riga, Latvia in 
2002, the prevalence of HIV among young 
IDU (<25 years of age) was higher  (25%) 
than among older IDU (14%). In Togliatti 
City in the Russian Federation, HIV 
prevalence in younger IDU was 58% 
compared to 51% among older IDU in 
2001. In contrast to the situation in the 
West, these two studies suggest that HIV 
prevalence was at least as high, if not 
higher, among young IDU (<25 years) than 
among older IDU in the East. 
 
1.4 HIV prevalence assessed in 
specific sub-populations 
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       ► Kyrgyzstan, 2004
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► Kazakhstan, 2006
Volgograd
Moscow Some HIV prevalence studies were 
conducted in specific sub-populations of 
IDU and data are presented for two such 
populations: 
• Prisons: separate results on HIV 
prevalence in prisons were available 
for 5 countries (Sweden, Bulgaria, 
Czech Republic, Armenia, Latvia) and 
are presented in Annexes 1.2-1.4. The 
study population was not clearly 
defined in all studies and the 
prevalence could have been under-
estimated in some that included non-
injecting drug users in the 
denominator. Self-reported prevalence 
from IDU prisoners in Sweden was 
>5% and, in other diagnostic testing 
studies from the other countries, HIV 
prevalence was less than 5% except in 
in seroprevalence study in Armenia 
(Annex 1.4).   
• Autopsies: data from studies of 
prevalence among deceased IDU were 
reported from three countries (Austria, 
Denmark and Germany), although the 
data from Austria also included IDU 
recruited from emergency services. In 
these studies, prevalence was >4% 
and in Austria and Germany, where 
results were available for several 
years, HIV prevalence levels have 
been reported as increasing (Annex 
1.2).  
 
1.5 Conclusion 
 
The overall picture of HIV prevalence 
among IDU in Europe remains highly 
heterogeneous. In many western and 
central European countries, HIV 
prevalence is low and the proportion of 
new HIV   diagnoses reported among IDU 
is <10% and decreasing. However, in 
► Russian Federation, 2003
% HIV+
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southern Mediterranean countries, 
although the number of newly diagnosed 
cases reported among IDU is declining, 
reported HIV prevalence remains high. 
The high long-lasting HIV prevalence 
reported among young  IDU (<25 years of 
age) in Catalonia reflect the ongoing 
transmission in this population [3]. Thus, 
despite the declines in the number of 
diagnosed cases of HIV among IDU in 
many western European countries, there 
is a need to continue to support and 
maintain the public health interventions 
that have been proven to control HIV in 
this population. 
 
In some countries in the East, the HIV 
epidemic started to spread intensively  
more  than a decade ago, and large and 
increasing numbers of new HIV diagnoses 
in several countries may reflect possible 
continuing transmission of HIV in this 
population, especially among younger IDU 
[1]. In the East, increasing heterosexual 
HIV transmission partly is attributed to IDU 
partners [43]. There is a need to 
implement, more widely, public health 
interventions (e.g. needle exchange 
programmes and opiate substitution 
therapy) that have proven effective in the 
control of HIV and other infectious 
diseases, reducing risk behaviours and 
producing better outcomes in terms of 
drug consumption and other illicit activities  
[44-47].  
 
National surveillance systems should 
inform policy makers and implementers of 
prevention programmes of the extent of 
the HIV epidemic and changes in the 
spread of HIV. At sub-national levels, 
surveillance should be integrated in the 
local level in order to supply data to 
support and develop local interventions.  
The existence of complex effective public 
health measures such as: interventions for 
the control of HIV among IDU (e.g. 
needles exchange programmes and opiate 
substitution therapy) [44;46;48-51] 
combined with delivery of health care 
services including antiretroviral treatment  
[52] provide policy makers with a viable 
response to control HIV in the population. 
 
The sites from where studies recruit IDU 
may have an impact on the HIV 
prevalence reported. Thus, IDU recruited 
from drug treatment centres often 
represent a population frequently using 
drugs but who are not representative of 
the whole drug-using population. In 
contrast, IDU recruited from community 
settings are important as they may include 
IDU who do not seek healthcare services, 
thereby reflecting a wider IDU population. 
  
There were regional differences in the 
surveillance sites across the WHO 
European Region. In the West, data were 
collected mainly from drug treatment sites, 
reflecting the developed network of health- 
care services for drug users. While in the 
East, more studies were performed in 
community settings and data from drug 
treatment centres were available only from 
a few countries.    
 
Caution must be exercised in the 
interpretation of trends data from 
seroprevalence studies, as a number of 
biases may operate, which are difficult to 
control. For example, at the beginning of 
an outreach programme, contact may be 
made with high risk IDU whereas, later, 
IDU at lower risk may be recruited. Thus, 
simple monitoring of HIV may indicate a 
reduction in prevalence which may not 
reflect the true situation [53].  
 
The surveillance of HIV in specific sub-
populations provides additional important 
information about the epidemic and 
valuable insight into certain sub-
populations. The data on IDU-related 
deaths include a proportion of individuals 
who did not seek healthcare services. 
Surveillance activities performed within 
prisons are not always easy to interpret as 
the data do not often describe the 
population clearly and may be sensitive to 
changes in the testing policy. In addition, 
the prison environment can lead to 
increased risk behaviour of certain 
prisoners compared to the general 
population. The possibility of confidential 
HIV testing should be assured for all 
prisoners. However, data obtained from 
prison settings for surveillance purposes 
raises certain ethical issues as voluntary 
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testing and confidentiality of HIV results 
may not always be assured. Therefore, 
using testing data for surveillance in 
prisons should be weighted carefully in 
order to avoid harm, and prisoners should 
benefit from the available interventions 
related to the reduction of the high risk 
behaviour [54].   
 
Second-generation surveillance among 
IDU, including behavioural surveys, needs 
to be encouraged in many European 
countries to support the development of 
HIV prevention interventions at both 
national and European levels. As the lack 
of consistency in the indicators of high risk 
behaviour employed hinders the 
comparison of the situation in different 
countries, the establishment of a core set 
of standardised sexual and injecting risk 
behaviour measures would contribute to 
international comparisons and provide 
better information for the development and 
evaluation of national approaches for HIV 
prevention among IDU. Surveillance data, 
including behavioural data, are important 
to formulate public health strategy, to 
support and expand HIV prevention 
programmes, drug and HIV treatment 
services. 
 
Novel methods for the detection of recent 
HIV infection such as detuned or  avidity of 
anti-HIV antibodies tests, which are still 
under development, are important for 
surveillance as they provide information on 
incident HIV cases, giving valuable 
information on the efficiency of different 
interventions and on the course of the 
epidemic [55-57].   
 
Injecting drug use remains one of the 
major transmission routes of HIV in 
Europe.  The need to ensure good 
surveillance is highlighted by the explosive 
epidemics that have been reported in the 
past [37;58;59]  as well as by the ability of 
the infection to cross national boundaries 
by a mobile population [60]. Thus, the 
surveillance of the HIV epidemic among 
IDU at the European level is needed to 
provide a better understanding of 
transmission and to guide the response to 
the epidemic.  
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Annex 1.1  HIV infections newly diagnosed in injecting drug users by country and year of report (2002-2006),
                   and cumulative totals, WHO European Region,  data reported by 31 December 2006
Geographic area
Country 2002 2003 2004 2005 2006
West
Andorra † – – 8 1 0 9 –
EU Austria ‡ 75 80 102 92 62 656 ‡ -17%
EU Belgium 22 32 25 13 11 703 -50%
EU Denmark 32 23 14 19 9 427 -72%
EU Finland 26 23 10 16 10 323 -62%
EU France § – 127 198 174 167 666 –
EU Germany 131 135 133 135 168 2,635 28%
EU Greece 17 11 11 20 17 301 0%
Iceland 1 1 1 0 1 21 0%
EU Ireland 50 49 71 66 57 1,327 14%
Israel 65 41 56 51 37 662 -43%
EU Italy || 239 207 190 138 – 774 –
EU Luxembourg 5 4 3 7 4 105 -20%
EU Malta † – – 2 0 2 4 –
Monaco ¶ – – – – – – –
EU Netherlands ** 182 81 46 30 17 616 -91%
Norway 13 15 17 15 12 528 -8%
EU Portugal 1,125 860 985 846 703 8,082 -38%
San Marino 0 0 0 0 0 11 –
EU Spain †† – 209 180 130 – 519 –
EU Sweden 31 32 31 25 35 1,001 13%
Switzerland 68 109 83 71 50 3,513 -26%
EU United Kingdom 147 132 169 177 187 4,593 27%
Total West 2,229 2,171 2,335 2,026 1,549 27,476  
Centre  
Albania 1 0 0 0 0 1 -100%
Bosnia & Herzegovina 1 0 3 2 3 19 200%
EU Bulgaria 2 0 7 13 34 66 1600%
Croatia 1 2 4 1 4 35 300%
EU Cyprus 0 0 0 1 0 6 –
EU Czech Republic 1 4 7 4 5 43 400%
EU Hungary 1 1 2 2 0 17 -100%
Macedonia, F.Y.R. 0 0 0 2 1 9 –
Montenegro 0 0 0 0 0 3 –
EU Poland 184 223 187 157 112 5,461 -39%
EU Romania 3 4 0 2 3 16 0%
Serbia ‡‡ 15 18 15 11 7 66 ‡‡ -53%
EU Slovakia 0 0 0 0 1 3 –
EU Slovenia 0 0 0 0 1 13 –
Turkey 5 5 6 8 6 124 20%
Total Centre 214 257 231 203 177 5,882 -17%
East  
Armenia 27 14 33 46 24 224 -11%
Azerbaijan 39 43 61 110 186 573 377%
Belarus 581 448 359 276 242 4,928 -58%
EU Estonia 702 346 247 192 191 2,396 -73%
Georgia 64 64 105 128 156 716 144%
Kazakhstan 500 502 433 636 1,162 5,422 132%
Kyrgyzstan 129 110 126 103 168 807 30%
EU Latvia 397 233 145 114 108 2,368 -73%
EU Lithuania 379 85 101 85 62 928 -84%
Moldova, Republic of 140 138 182 228 236 2,099 69%
Russian Federation 18,503 12,174 10,200 10,283 11,161 166,044 -40%
Tajikistan 17 33 105 142 99 435 482%
Turkmenistan 0 0 0 0 0 0 –
Ukraine 4,587 4,815 5,778 6,270 7,127 59,619 55%
Uzbekistan 631 918 831 1,140 1,454 5,571 130%
Total East 26,696 19,923 18,706 19,753 22,376 252,130 -16%
Total European Union (EU) 3,751 2,901 2,866 2,458 1,966 34,049 -48%
Total WHO European Region 29,139 22,351 21,272 21,982 24,102 285,488 -17%
Cumulative total 
reported *
Change in no. 
reported HIV 
cases among 
IDU: 2002-2006
Year of report
 
EU Countries which constitute the European Union as of 1 January 2007.
* Cumulative totals available since the beginning of reporting (see Reference no. 1 in Commentary).
† New HIV reporting system started in 2004
‡ Cumulative total since 1998 (data not available by transmission group prior to 1998).
§
||
¶ Data not available.
**
††
‡‡ Cumulative total since 2002 (data not available by transmission group prior to 2002); data not available from Kosovo from 1999.
New HIV reporting system started in 2003 (data March-December for 2003).
HIV reporting exists in 10 regions/provinces (Bolzano, Friuli Venezia-Giulia, Lazio, Liguria, Modena, Piemonte, Rimini, Sassari,Trento, Veneto); data (presented by 
year of diagnosis) available for all 10 regions/provinces for 2002-2005 only.
New HIV reporting system started in 2002; 2002 data include many cases diagnosed in previous years.  Data prior to 2002 are from a national cohort of HIV positive 
adults receiving antiretroviral therapy.
HIV reporting exists some of the 19 Autonomous regions but data (presented by year of diagnosis) are only available for 8 regions (Balearic Islands, Basque 
Country, Canary Islands, Catalonia, Ceuta, Extremadura, La Rioja, Navarre) comprising 32% of the total Spanish population
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Annex 1.2 HIV prevalence studies and diagnostic testing among injecting drug users (IDU): numbers tested 
and HIV prevalence by country, 2001-2006, WHO European Region, West
Country 2001  
Coverage Data Population Site
N
tested %HIV+
Austria
 National  DT Drug-related deaths/emergencies Autopsies, emergency services 139 5.8
 Vienna  DT IDU NEP, LTS 153 1.3
Belgium    
 French Community SR IDU DTC 267 3.4
 Flemish Community DT IDU DTC 118 1.7
 Flemish Community: Antwerp SP IDU DTC, NEP 254 5.9
Denmark         
 National  SP IDU Autopsies – –
Finland    
Helsinki, Tampere, Vantaa DT IDU NEP 
  - Helsinki 615 1.5
  - Tampere, Vantaa * 516 0.0
Helsinki, Vantaa SP (UAT) † IDU NEP  139 0.7
  - Helsinki 59 0.0
France    
Marseille SP (UAT) ‡ Drug users (current & former) § DTC, NEP, street, GP, residential c – –
 Paris, Montpellier, Mulhouse SR Drug users in drug treatment ¶ DTC, GP, NEP  – –
 12 cities ** SR IDU NEP, LTS, street 350 13.7
 5 cities SP-UAT IDU DTC, GP, street, residential centre – –
  - Bordeaux    – –
  - Lille    – –
  - Marseille    – –
  - Paris    – –
  - Strasbourg    – –
Germany    
 National SR IDU  DTC  219 4.1
 National DT Drug-related deaths Autopsies †† – –
 Frankfurt SR IDU  Street – –
Greece    
 National DT IDU DTC, LTS, STI, VCT 1,099 1.5
  - Attica (Athens)   1,040 1.4
  - <25 years   – –
 National DT IDU DTC – –
  - Attica (Athens) – –
Ireland    
 Greater Dublin (South-west region) SP IDU   DTC – –
Italy    
 National ‡‡ SP Drug users in drug treatment §§ DTC  71,769 14.8
  - Campania 9,161 3.6
  - Lombardy 14,670 26.1
  - Sardinia 1,889 26.5
  - Tuscany 4,170 10.0
 National SP STI patients  STI clinic – –
Luxembourg    
 National SR IDU DTC, NEP, prison 205 3.4
Surveillance methods and population studied
 
Data: Site: *
DT: Diagnostic testing DTC: Drug treatment centres
SP: Seroprevalence study GP: General practictioners † Saliva testing
SR: Self-reported HIV serostatus LTS: Low threshold services for drug users ‡ Dried blood spots
UAT: Unlinked anonymous testing NEP: Needle exchange programmes § 22% current injectors (2002)
STI: Sexually transmitted infection clinics || Self-reported prevalence = 23% (36/159)
VCT: HIV volontary counselling & testing centres ¶ 26% injected in last month (2002)
Ref.: References, see Commentary ** Cities not specified
†† Autopsy rates 25-100% by state
‡‡
§§ Drug users attending public DTC; 5-10% non-injectors
2002, 2004 & 2005: data for Vantuaa only; 2003: Tampere 
only
Data from 21 regions (4 shown separately to reflect range 
of levels and trends)
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Annex 1.2 HIV prevalence studies and diagnostic testing among injecting drug users (IDU): numbers tested 
(Cont.)          and HIV prevalence by country, 2001-2006, WHO European Region, West
2002  2003  2004  2005  2006  Country  
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+ Ref. Coverage
Austria
139 3.6 130 8.5 130 8.5 118 11.9 112 7.1 5 National  
151 4.0 151 4.0 159 6.3 163 3.1 113 1.8 5 Vienna  
Belgium
180 0.0 239 4.6 122 9.0 – – – – 4 French Community 
62 1.6 82 1.2 97 4.1 – – – – 4,6 Flemish Community 
259 6.2 287 5.6 295 6.1 340 7.1 – – 4,6 Flemish Community: Antwerp 
           Denmark
– – – – 214 4.2 – – – – 7 National  
Finland
4 Helsinki, Tampere, Vantaa 
555 0.4 475 0.4 564 0.7 416 0.0 – –   - Helsinki 
227 0.0 257 0.0 302 0.0 373 0.0 – –   - Tampere, Vantaa *
296 0.7 – – 231 1.7 – – – – 4 Helsinki, Vantaa 
212 0.9 – – 148 2.7 – – – – 4   - Helsinki 
France
133 21.8 || – – – – – – – – 8 Marseille 
326 23.0 – – – – – – – – 9 Paris, Montpellier, Mulhouse 
358 13.7 563 13.7 – – – – – – 4 12 cities **
– – – – 817 11.0 – – – – 10,11 5 cities 
– – – – 123 3.3 – – – –   - Bordeaux 
– – – – 100 1.0 – – – –  - Lille 
– – – – 129 31.8 – – – –  - Marseille 
– – – – 335 11.0 – – – –  - Paris 
– – – – 130 3.8 – – – –  - Strasbourg 
Germany
608 6.2 785 3.7 843 3.7 – – – – 4 National 
933 4.6 1,927 3.9 1,077 4.0 1,326 5.3   4 National 
141 12.8 145 17.2 147 12.2 – – – – 4 Frankfurt 
Greece
1,328 0.4 1,378 0.8 1,377 0.7 1,023 0.3 – – 4 National 
996 0.5 1,062 0.8 884 0.8 687 0.2 – –  - Attica (Athens) 
354 0.0 251 0.0 317 0.3 185 0.0 – –  - <25 years 
258 0.8 653 0.2 738 0.3 739 0.3 – – 4 National 
127 0.0 169 0.0 447 0.2 445 0.2 – –  - Attica (Athens) 
Ireland 
307 10.7 – – – – – – – – Greater Dublin (South-west region) 
Italy
70,075 14.7 71,989 14.2 67,683 13.9 65,848 13.8 – – 4 National ‡‡
8,636 2.8 9,804 3.0 9,485 2.6 7,708 2.5 – –  - Campania 
14,039 27.2 14,300 25.6 13,067 24.8 13,075 23.2 – –  - Lombardy 
1,528 25.7 1,364 29.6 1,702 24.7 1,542 27.6 – –  - Sardinia 
4,237 11.9 3,972 11.4 3,193 13.7 3,464 9.1 – –  - Tuscany 
– – 259 13.1 254 10.6 – – – – National 
Luxembourg
245 4.1 221 4.5 196 5.1 227 4.0 – – 4 National  
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Annex 1.2 HIV prevalence studies and diagnostic testing among injecting drug users (IDU): numbers tested 
and HIV prevalence by country, 2001-2006, WHO European Region, West
Country 2001  
Coverage Data Population Site
N
tested %HIV+
(Cont.)
Netherlands    
Rotterdam SP (UAT) * Current IDU DTC, street  – –
Norway    
 National SP IDU † DTC, rehabilitation – –
  - Eastern Health Region    – –
  - Southern health Region    – –
  - Western Health Region    – –
  - Central Health Region    – –
  - Northern Health Region    – –
 Oslo SP IDU NEP 186 0.5
Portugal    
 National DT Drug users (IDU status unknown) DTC, rehabilitation 2,683 13.6
   - Lisbon 728 19.6
   - North 877 17.4
   - Centre 908 6.1
   - Algarve 133 7.5
 National DT Drug users (IDU status unknown) DTC, therapeutic community 3,863 17.8
 National DT Drug users (IDU status unknown) DTC, detoxification unit 2,694 16.8
Spain    
 National (18 cities) § DT IDU seeking HIV testing VCT, STI 899 14.1
 National, excl. Madrid, La Rioja DT IDU DTC 7,528 33.7
  - <25 years 809 14.0
  - new injectors (<2 years) 179 21.2
 Catalonia DT IDU DTC 1,244 37.5
  - male 1,038 36.9
  - female 206 40.8
  - <25 years 120 13.3
Sweden    
 Stockholm    SR IDU   Prison – –
Switzerland    
 National DT IDU seeking HIV testing VCT 73 2.7
United Kingdom    
England & Wales || SP (UAT) ¶ IDU  DTC, NEP, LTS, street, hosp 2,855 1.0
 - London   515 4.5
 - outside London   2,340 0.3
 - <25 years   629 0.5
 - new injectors (<3 years)   551 0.4
 Scotland ** DT IDU seeking HIV testing  VCT, DTC, STI, hospital, GP, priso 2,154 0.8
  - Greater Glasgow   660 0.5
  - Lothian (Edinburgh)    337 2.4
  - Tayside (Dundee)   146 2.1
  - <25 years   686 0.3
Surveillance methods and population studied
 
Data: Site:
DT: Diagnostic testing DTC: Drug treatment centres * Serum or saliva testing
SP: Seroprevalence study GP: General practictioners †
SR: Self-reported HIV serostatus LTS: Low threshold services for drug users
UAT: Unlinked anonymous testing NEP: Needle exchange programmes §
STI: Sexually transmitted infection clinics  
Ref.: References, see Commentary VCT: HIV volontary counselling and testing centres || N. Ireland included from 2002
¶ Saliva testing
** ¨Denominator study¨
"EPI-VIH prospective" study: current and former IDU 
tested for the first time; 
IDU tested for HIV at entry into 
drug assisted rehabilitation 
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Annex 1.2 HIV prevalence studies and diagnostic testing among injecting drug users (IDU): numbers tested 
(Cont.)          and HIV prevalence by country, 2001-2006, WHO European Region, West
2002  2003  2004  2005  2006  Country  
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+ Ref. Coverage
Netherlands
452 9.5 – – – – – – – – 12 Rotterdam 
Norway
– – – – – – 2,786 3.6 3,349 3.2 13  National 
– – – – – – 1,076 6.2 1,322 5.4  - Eastern Health Region 
– – – – – – 752 2.5 869 2.0  - Southern health Region 
– – – – – – 612 1.5 762 1.7  - Western Health Region 
– – – – – – 231 2.2 272 2.2  - Central Health Region 
– – – – – – 115 0.0 114 0.0  - Northern Health Region 
410 1.2 229 0.9 264 0.4 258 0.4 231 1.3 14 Oslo 
Portugal
1,688 10.8 1,443 15.0 1,154 12.0 917 12.0 – – 4 National 
– – – – – – – – – –   - Lisbon 
– – – – – – – – – –   - North 
– – – – – – – – – –   - Centre 
– – – – – – – – – –   - Algarve 
3,930 16.0 3,966 16.0 3,993 17.0 3,962 16.0 – – 4 National 
2,764 13.3 – – – – – – – – 4 National 
Spain
759 9.7 673 11.1 599 11.5 534 10.1 – – 15,16 National (18 cities) §
5,268 32.0 8,033 27.2 7,046 25.4 – – – – 4 National, excl. Madrid, La Rioja 
555 12.1 862 3.8 614 3.6 – – – –  - <25 years 
114 17.5 – – – – – – – –  - new injectors (<2 years) 
961 33.0 – – – – – – – – 17 Catalonia 
805 32.2 – – – – – – – –  - male 
156 37.2 – – – – – – – –  - female 
98 11.2 – – – – – – – –  - <25 years 
Sweden
– – – – – – 379 5.5 358 6.4 4 Stockholm    
Switzerland
97 3.1 79 1.3 72 1.4 – – – – National 
United Kingdom
2,796 0.9 2,702 1.2 2,686 1.4 3,176 1.6 3,240 1.3 18 England & Wales ||
608 3.6 801 2.9 645 3.9 628 3.2 593 4.0  - London 
2,188 0.2 1,901 0.5 2,040 0.6 2,548 1.3 2,646 0.7  - outside London 
465 0.4 462 0.4 460 0.0 475 1.1 455 0.4  - <25 years 
400 0.3 386 0.8 345 0.6 397 1.3 388 0.8  - new injectors (<3 years) 
2,040 0.4 2,008 0.4 1,947 0.6 2,117 0.5 2,140 0.7 19 Scotland **
615 0.0 553 0.5 406 0.2 432 0.5 441 0.7  - Greater Glasgow 
371 1.1 373 0.3 589 0.7 662 1.2 574 0.7  - Lothian (Edinburgh)  
170 0.0 148 2.0 151 0.0 157 1.3 135 2.2  - Tayside (Dundee) 
649 0.2 584 0.2 – – – – – –  - <25 years  
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Annex 1.3. HIV prevalence studies and diagnostic testing among injecting drug users (IDU):  
 numbers tested and HIV prevalence by country, 2001-2006, WHO European Region, Centre
Country
 Coverage Data Population Site
N
tested %HIV+
Bosnia & Herzegovina
Sarajevo, Mostar DT IDU DTC, hospital – –
Bulgaria
Cities * SP IDU NEP, street, mobile medical unit – –
Sofia SP IDU DTC, NEP – –
Sofia DT IDU DTC, NEP, LTS,VCT 689 0.0
Sofia DT IDU Prison – –
Croatia
National DT IDU STI, hospital, VCT, DTC, NEP 724 0.7
Czech Republic
National DT IDU DTC, NEP, LTS, STI, hospital 2,169 0.05
National DT IDU   Prison – –
National SR IDU   DTC † – –
 - <25 years – –
National DT Drug users (IDU status unknown) LTS – –
Prague, Bohemia, Moravia SP ‡ IDU DTC§, NEP, LTS, street 961 0.0
Hungary
National SP IDU DTC 315 0.0
Poland
National || DT IDU seeking HIV testing  VCT, DTC, STI 2,952 9.1
Gdansk region SP IDU DTC, street – –
 - drug treatment centres – –
3 regions ¶ SP IDU DTC, NEP, street – –
Regional SP IDU DTC, NEP, street – –
 - Lubuskie – –
 - Slaskie  – –
 - Warsaw – –
Serbia  
Belgrade DT Drug users seeking medical assistance DTC 902 0.4
Belgrade, Vojvodina ** DT IDU VCT – –
Slovakia
Bratislava, Kosice DT Drug users seeking medical assistance DTC 590 0.0
Slovenia
National DT IDU DTC – –
Ljubljana and Koper regions †† SP (UAT) ‡ Drug users DTC 153 0.0
Ljubljana SP (UAT) ‡ IDU NEP – –
2001Surveillance methods and population studied
 
Data: Site: *
DT: Diagnostic testing DTC: Drug treatment centres
SP: Seroprevalence study GP: General practictioners † Opiate substitution centres
SR: Self-reported HIV serostatus LTS: Low threshold services for drug users ‡ Saliva testing
UAT: Unlinked anonymous testing NEP: Needle exchange programmes § At first or repeat (6 monthly) visits
STI: Sexually transmitted infection clinics || Data from all HIV testing labs
VCT: HIV volontary counselling and testing centres ¶ Dolnoslaskie, Lubeskie, Warminsko-Mazurskie
Ref.: References, see Commentary ** 50% of the country population
†† Ljubljana only in 2003
2004: Sofia, Plovdiv, Burgas, Pleven, Varna; 2005: Sofia, Plovdiv, 
Burgas, Pleven, Varna, Blagoevgrad, Pazardzhik, Rousse
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Annex 1.3. HIV prevalence studies and diagnostic testing among injecting drug users (IDU):  
(Cont.)           numbers tested and HIV prevalence by country, 2001-2006, WHO European Region, Centre
Country
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+ Ref. Coverage
Bosnia & Herzegovina
– – 255 0.8 – – – – – – Sarajevo, Mostar 
Bulgaria
– – – – 675 0.6 1,199 0.5 – –  Cities *
– – 312 0.3 – – – – – – 20   Sofia 
719 0.1 992 0.1 1,203 0.7 827 0.4 – – 4     Sofia 
– – – – – – 115 2.6 – – 4     Sofia 
Croatia
785 1.3 – – – – – – – – National 
Czech Republic
1,536 0.0 985 0.1 1,609 0.0 1,374 0.1 – – 4    National 
674 0.4 – – – – – – – – 4    National 
307 1.3 – – – – – – – – 4    National 
173 0.0 – – – – – – – –  - <25 years 
522 0.0 – – – – – – – – 4    National 
735 0.0 652 0.0 222 0.0 449 0.2 – – 4    Prague, Bohemia, Moravia 
Hungary
607 0.3 331 0.0 – – – – – – 4    National 
Poland
2,626 6.8 – – – – – – – – 21  National ||
166 29.5 – – – – – – – – Gdansk region 
105 36.2 – – – – – – – –  - drug treatment centres 
– – – – – – 338 24.9 – – 3 regions ¶
– – – – 418 12.9 – – – – 22  Regional 
– – – – 158 8.9 – – – –  - Lubuskie 
– – – – 60 13.3 – – – –  - Slaskie  
– – – – 200 16.0 – – – –  - Warsaw 
Serbia  
853 1.2 – – – – – – – – Belgrade 
– – 368 0.8 1,099 0.4 795 0.8 1,281 0.2 Belgrade, Vojvodina **
Slovakia
911 0.0 970 0.0 469 0.0 554 0.0 580 0.0 Bratislava, Kosice 
Slovenia
648 0.0 707 0.0 476 0.4 – – – – 4    National 
182 0.0 333 0.0 233 0.0 300 0.0 – – 23  Ljubljana and Koper regions ††
– – 148 0.0 233 0.0 188 0.0 – – 4    Ljubljana  
20062005200420032002
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Annex 1.4.      HIV prevalence studies and diagnostic testing among injecting drug users (IDU): numbers tested
     and HIV prevalence by country, 2001-2006, WHO European Region, East  
Country
 Coverage Data Population Site
N
tested %HIV+
Armenia     
 National DT IDU DTC – –
 4 cities * SP (UAT) IDU VCT, DTC, street – –
 Prisons SP Prisoners † Prisons – –
Azerbaijan     
National DT IDU DTC, hospital 2,831 2.2
 Cities  SP IDU 
   - Baku DTC, hospital, street – –
   - Lenkoran Street – –
Belarus     
 National DT IDU DTC, hospital 5,558 3.2
  - Gomel region  1,269 7.2
  - Minsk region  1,953 3.3
 Cities or regions SP (UAT) ‡ IDU NEP, street
  - Baranovichi    – –
  - Borisov    – –
  - Brest    – –
  - Minsk      – –
  - Mogilev    – –
  - Molodechno    – –
  - Pinsk    – –
  - Soligorsk    – –
  - Svetlogorsk    – –
  - Vitebsk    – –
  - Zlobin    – –
  - Rethitsa    – –
  - Grodno    – –
 - Gomel – –
Estonia     
 National DT IDU DTC, NEP, GP, STI, hospital, VCT 2,078 13.0
 2 cities SP ‡ IDU NEP
  - Tallinn    – –
  - Kohtla-Jarve  §    – –
 Tallinn SP || IDU NEP – –
Georgia
 National DT IDU DTC, prison 207 22.2
 National SP IDU DTC, NEP, hospital, VCT, prison – –
Kazakhstan     
 Prisons DT Prisoners ¶ Prison – –
 4 regions SP ‡ IDU NEP, street – –
  - Karagandinskaya – –
  - Pavlodarskaya – –
  - South Kazakhstanskaya – –
  - West Kazakhstanskaya – –
Kyrgyzstan   
 2 cities SP ‡ IDU Street
  - Bishkek – –
  - Osh – –
2001Surveillance methods and population studied
 
 
 
 
 
 
Data: Site: *
DT: Diagnostic testing DTC: Drug treatment centres
SP: Seroprevalence study GP: General practictioners † HIV prevalence among IDU prisoners = 10%
SR: Self-reported HIV serostatus LTS: Low threshold services for drug users ‡ Dried blood spots
UAT: Unlinked anonymous testing NEP: Needle exchange programmes § Small sample size, high risk population included
STI: Sexually transmitted infection clinics || Residual blood in used needles
Ref. References, see commentary VCT: HIV volontary counselling and testing centres ¶ 45% are IDU
2002 and 2005: Yerevan, Shirak, Syunik, Ararat 
Marzes; 2006: Yerevan, Shirak, Syunik, Lori
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Annex 1.4. HIV prevalence studies and diagnostic testing among injecting drug users (IDU): numbers tested
(Cont.)  and HIV prevalence by country, 2001-2006, WHO European Region, East
Country
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+ Ref. Coverage
          Armenia
226 7.1 – – – – – – – – National 
201 14.9 – – – – 280 9.3 151 9.3 24  4 cities *
438 5.5 – – – – – – – – 24  Prisons 
   Azerbaijan
2,931 0.0 2,964 0.8 2,164 1.2 3,120 1.8 3,568 2.2 National 
25 Cities  
– – 200 13.0 – – – – – –    - Baku 
– – 200 19.5 – – – – – –    - Lenkoran 
          Belarus
4,604 4.4 3,589 3.7 2,749 10.9 – – 2,492 16.7 26  National 
746 8.4 518 8.3 – – – – – –   - Gomel region 
1,618 5.9 1,328 4.7 – – – – – –   - Minsk region 
27  Cities or regions 
100 6.0 – – – – – – 100 0.0   - Baranovichi 
100 1.0 – – – – – – 101 3.0   - Borisov 
200 5.0 – – – – – – 150 8.0   - Brest 
400 23.0 – – – – – – 317 11.7   - Minsk   
133 4.5 – – – – – – 170 1.2   - Mogilev 
112 2.7 – – – – – – – –    - Molodechno 
– – – – – – – – 150 18.7   - Pinsk 
– – – – – – – – 200 23.0   - Soligorsk 
– – – – – – – – 200 37.5   - Svetlogorsk 
– – – – – – – – 150 8.7   - Vitebsk 
– – – – – – – – 150 52.0   - Zlobin 
– – – – – – – – 100 20.0   - Rethitsa 
– – – – – – – – 150 1.3   - Grodno 
– – – – – – – – 200 17.5  - Gomel 
          Estonia
1,186 6.2 – – – – – – – – 4  National 
28  2 cities 
– – – – – – 350 54.3 – –   - Tallinn 
– – – – – – 99 89.9 – –   - Kohtla-Jarve  §
– – – – 159 56.0 – – – – 29  Tallinn 
Georgia
572 7.0 – – – – – – – –  National 
  1,660 3.9 – – – – – –  National 
          Kazakhstan
– – 17,845 0.7 19,374 0.7 21,928 1.0 22,428 1.6 Prisons 
– – 1,040 3.9 2,904 2.8 3,775 3.4 4,553 3.4  4 regions 
– – 270 2.2 350 1.1 282 2.1 708 4.1   - Karagandinskaya 
– – 250 6.4 252 7.1 250 10.4 600 7.8   - Pavlodarskaya 
– – 270 5.9 390 8.5 300 8.0 300 7.3   - South Kazakhstanskaya 
– – 250 1.2 250 1.2 250 0.8 250 2.0   - West Kazakhstanskaya 
          Kyrgyzstan
  2 cities 
– – – – 264 1.1 250 2.4 250 0.8   - Bishkek 
– – – – 250 11.6 250 13.6 250 14.0   - Osh 
200620052002 2003 2004
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Annex 1.4. HIV prevalence studies and diagnostic testing among injecting drug users (IDU): numbers tested
 and HIV prevalence by country, 2001-2006, WHO European Region, East
Country
 Coverage Data Population Site
N
tested %HIV+
(Cont.)
Latvia     
 National DT IDU DTC, hospital 2,203 13.7
 National DT IDU Hospital, police (arrests) 687 12.2
 Riga DT IDU VCT 1,068 17.3
 Riga (region) and Tukums SP IDU NEP, street – –
  - <25 years – –
Riga, Olaine SP IDU 
 12 cities * SR IDU NEP, VCT – –
Prisons DT Prisoners † Prison 7,267 4.7
Lithuania     
 National DT IDU DTC, NEP, hospital 1,543 1.7
  - Vilnius – –
 Vilnius SP IDU NEP – –
 Klaipėda SP IDU LTS – –
Moldova, Republic     
 National DT IDU DTC, VCT 3,865 3.6
 5 cities ‡ SP § IDU NEP 1,053 27.6
Russian Federation     
 National DT IDU – 491,526 6.1
 Saint-Petersbourg SP (UAT) IDU NEP 252 35.7
 Togliatti City SP (UAT) IDU Community 418 56.0
  - <25 years 197 58.4
 Orel region DT IDU DTC, prison 2,700 11.6
 Saint-Petersbourg SP IDU Street – –
3 cities SP(UAT) IDU Street
 - Moscow    – –
 - Volgograd    – –
 - Barnaul    – –
Tajikistan     
 2 cities SP(UAT) || IDU Street – –
 - Dushanbe – –
 - Khujand – –
Ukraine     
 National DT IDU – 40,747 11.1
  - Kiev region  3,015 22.1
  - Nikolaiev 1,637 27.3
  - Odessa  964 15.4
 Cities or regions SP ¶ IDU NEP, street
  - Donetsk – –
  - Kharkiv – –
  - Luck – –
  - Nikolaiev   – –
  - Odessa – –
  - Poltava – –
  - Simferopol – –
 Cities SP || IDU Street
  - Makeevka (Donetsk)    – –
  - Kiev      – –
  - Odessa    – –
Uzbekistan     
 Tashkent SP || IDU Street – –
Surveillance methods and population studied 2001
 
 
 
 
 
 
 
Data: Site: 
DT: Diagnostic testing DTC: Drug treatment centres
*
SP: Seroprevalence study GP: General practictioners † Proportion of IDU among HIV+: 60-90%
SR: Self-reported HIV serostatus LTS: Low threshold services for drug users ‡ Chisinau, Balti, Falesti, Soroca, Orche
UAT: Unlinked anonymous testing NEP: Needle exchange programmes § Residual blood in used needles
STI: Sexually transmitted infection clinics || Dried blood spots
Ref.: References, see Commentary VCT: HIV volontary counselling and testing centres ¶ Residual blood in used needles, serum
Riga, Kuldiga, Tukums, Olaine, Bauska, Jelgava, 
Jekabpils, Liepaja, Jurmala, Talsi, Ogre, Kekava
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Annex 1.4. HIV prevalence studies and diagnostic testing among injecting drug users (IDU): numbers tested
(Cont.)  and HIV prevalence by country, 2001-2006, WHO European Region, East
Country
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+
N
tested %HIV+ Ref. Coverage
          Latvia
1,178 13.1 987 6.6 212 10.4 363 8.5 349 11.2  National 
185 14.6 – – – – – – – –  National 
832 13.5 447 15.2 256 2.0 518 12.5 293 4.4 30  Riga 
250 20.8 205 22.0 – – 325 21.8 – – 31  Riga (region) and Tukums 
159 24.5 107 19.6 – – – – – –   - <25 years 
Riga, Olaine 
    – – – – 382 13.9  12 cities *
6,684 4.4 6,209 3.6 5,369 3.4 3,094 4.5 2,600 4.4  Prisons 
          Lithuania
2,831 1.0 1,112 2.4 1,420 1.2 1,375 3.5 1,105 1.3  National 
641 0.6 375 1.1 469 0.2 345 1.2 – – 32   - Vilnius 
– – – – – – 681 3.2 158 1.3 32,33  Vilnius 
– – – – – – 171 27.5 – – 32  Klaipėda 
          Moldova, Republic
4,697 2.0 4,648 1.6 3,720 2.1 3,516 3.3 4,277 2.1  National 
  524 22.1 – – – – – – 34  5 cities ‡
          Russian Federation
331,112 3.2 279,509 2.2 257,889 1.9 265,696 2.1 281,952 2.1 35  National 
– – – – – – – – – – 36  Saint-Petersbourg 
– – – – – – – – – – 37  Togliatti City 
– – – – – – – – – –   - <25 years 
– – – – – – – – – – 38  Orel region 
– – – – – – – – 412 47.1 39  Saint-Petersbourg 
40  3 cities 
– – 403 13.6 – – – – – –   - Moscow 
– – 477 2.7 – – – – – –   - Volgograd 
– – 499 8.8 – – – – – –   - Barnaul 
  1,379         Tajikistan
– – – – – – – – – –   2 cities 
– – – – – – 403 17.9 400 24.0  - Dushanbe 
– – – – – – 200 11.5 200 23.0  - Khujand 
           Ukraine
21,472 12.1 33,004 14.7 32,184 14.8 32,291 14.9 33,094 16.5  National 
1,956 23.5 2,493 30.7 2,166 33.1 2,613 24.4 2,800 38.3   - Kiev region  
840 24.5 1,476 26.1 1,320 30.1 1,721 25.8 1,979 22.7   - Nikolaiev 
612 14.7 945 18.6 1,646 21.3 1,129 19.5 1,571 15.0   - Odessa  
Cities or regions 
250 40.0 – – 250 41.6 250 40.8 265 34.0   - Donetsk 
250 16.8 – – 100 14.0 100 23.0 103 18.4   - Kharkiv 
250 32.0 – – 250 32.8 300 26.0 250 37.6   - Luck 
250 53.2 – – – – 250 66.4 250 46.0   - Nikolaiev   
259 58.3 – – 363 58.1 269 41.3 256 54.7   - Odessa 
250 31.6 – – 250 28.4 250 19.6 250 62.8   - Poltava 
250 28.0 – – 244 59.0 380 51.1 248 49.2   - Simferopol 
41  Cities 
– – – – – – 287 14.3 – –   - Makeevka (Donetsk) 
– – – – – – 267 23.6 – –   - Kiev   
– – – – – – 224 36.6 – –   - Odessa 
         Uzbekistan
– – – – 401 21.9 403 17.9 400 24.0 42  Tashkent 
2003 2004 200620052002
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2. HIV prevalence in blood 
donations 
 
 
Key points 
• In most central and western European 
countries, the prevalence of HIV in blood 
donations remains low (<5 per 100,000);  
• In many eastern European countries, high 
and increasing levels of HIV prevalence in 
blood donations (>10 per 100,000) have 
been reported.   
 
Recommendations for surveillance  
• Ensure regular reporting of data from 
blood screening;  
• Report, separate data on HIV prevalence 
in first time and repeat blood donors. 
 
Recommendations for public health  
• Ensure that basic screening measures are 
available for all blood donations in all 
European countries, including 
implementation of quality-assured testing 
procedures and improved performance 
standards;  
• Strengthen measures to guarantee the 
safety of the blood supply, especially the 
improvement of donor selection.   
 
  
 
 
2.1  Introduction 
 
Monitoring HIV prevalence in blood 
donations is important for surveillance as it 
provides an indication of the relative safety 
of the blood supply across countries and 
over time. In addition, it provides some 
indication of HIV trends in the population, 
although trends in prevalence in blood 
donations are also clearly affected by 
changes in the effectiveness of donor 
selection. 
  
The data presented in this section cover 
the period 1990 to 2006 and update those 
presented in report No. 72 published in 
2006 [1]. Annex tables present data on 
HIV prevalence in blood donations by 
country for 2001-2006 (Annex 2.1) and, for 
certain countries, separate data on HIV  
prevalence in donations from first-time and 
repeat donors are available (Annexes 2.2. 
and 2.3). 
 
2.2 HIV prevalence in blood donations 
 
In 2006, the overall HIV prevalence in 
blood donations in the WHO European 
Region was 10.3 per 100,000 donations 
(data from 36 of the 53 countries, Annex 
2.1)[2-13]. However, wide variations were 
observed, with much higher levels in 
eastern European countries (Figure 2.1). 
In 2006, the prevalence of HIV ranged 
from 0 (i.e. no HIV positive blood 
donations detected) in six countries to 
49.0 per 100,000 donations in the 
Republic of Moldova and 127.1 per 
100,000 donations in Ukraine (Figure 2.1, 
Annex 2.1). 
 
Figure 2.1: HIV prevalence in blood 
donations (per 100,000) WHO European 
Region, 2001-2006 * 
 
 
*Latest available data.  For Albania and Uzbekistan data 
were available for 2000, but were not included in this map   
 
In western European countries, the 
prevalence of HIV among blood donations 
has declined from 5.2 (22 countries 
reporting) in 1990 to 1.2 per 100,000 
donations in 2006 (12 countries) (Figure 
2.2). In central European countries, during 
the same period, the prevalence of HIV 
among blood donations rose from 1.6 (11 
countries reporting) in 1990 to a maximum 
of 3.8 per 100,000 donations in 2006 (12 
countries) (Figure 2.2). In contrast, in 
eastern Europe, the prevalence of HIV in 
blood donations has increased 
dramatically from <1 in 1995 (10 countries 
reporting) to 37,6 per 100,000 blood 
donations in 2006 (11 countries) (Figure 
2.2). 
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Figure 2.2: HIV prevalence in blood 
donations per 100,000 blood donations in 
the WHO European Region, 1990-2006. 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.1 Eastern Europe 
The  most dramatic rise in the number of 
HIV positive donations was in Ukraine, 
where the rate of HIV positive donations 
has increased from 2.1 per 100,000 
donations in 1995 to 128.4 in 2004, and 
has since stabilised with a reported 
prevalence of 127.1 per 100,000 in 2006 
(Figure 2.3, Annex 2.1). 
 
Figure 2.3: HIV prevalence in blood 
donations (per 100,000) in six eastern 
European countries, 1994-2006. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Important increases in the prevalence of 
HIV in blood donations have also been 
observed in other eastern European 
countries (Figures 2.3, 2.4; Annex 2.1).  In 
2006, the second highest prevalence after 
the Ukraine was reported from Moldova 
(49.0 per 100,000 donations) following 
rapid increases since the mid 1990s.  
 
Other countries with high (>15/100,00) 
prevalence of HIV in blood donations 
include Georgia, Kazakhstan, Kyrgyzstan 
and the Russian Federation, where rapid 
increases in HIV have been reported in 
recent years (Figure 2.3).   For example, in 
the Russian Federation, between 1999 
and 2001, HIV prevalence doubled each 
year, reaching 29.6 per 100,000 in 2001, 
since when it has declined to 22.8 in 2006. 
 
Of note, data on HIV prevalence in blood 
donations have not been available since 
1998 for Tajikistan and Turkmenistan and 
since 2000 for Uzbekistan. 
 
Figure 2.4: HIV prevalence in blood 
donations (per 100,000) in the Baltic 
States, 1994-2006. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rapid increases in HIV prevalence in 
blood donations have also been reported 
in the Baltic States (Estonia and Latvia). In 
Estonia, prevalence increased from 
4.0/100,000 donations in 1998 to a 
maximum of 54.0/100,000 in 2002, since 
when it has declined to 16.5/100,000 in 
2006 (Figure 2.4). In Latvia, a smaller 
increase has  been reported, from 
2.3/100,000 in 1998 to 11.8/100,000 in 
2006, with a peak observed in 2005 
(22.9/100,000). In Lithuania, HIV 
prevalence has remained low 
(<5/100,000). 
 
 
2.2.2 Central Europe 
In the central European countries, the 
prevalence of HIV-positive blood 
donations has remained stable, at below 5 
per 100,000 donations in most countries 
(Figure 2.2). In 2006, four countries 
reported zero HIV-positive donations: 
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Bosnia & Herzegovina, Cyprus, Slovenia 
and Slovakia (Annex 2.1).  
HIV prevalence of >5 HIV+ per 100,000 
donations have been reported for at least 
one year in Bulgaria (8.1 in 2003), 
Romania (5.8 in 2006), Serbia (9.5 in 
2004), and Turkey (7.8 in 2006) (Annex 
2.1). In Romania, after the peak level 
reported in 1995 (35/100,000), prevalence  
ranged from 4.8/100,000 to  9.5/100,000 in 
2001 and then decreased to 5.8/100,000 
in 2006 (Figure 2.5). In Bulgaria, 
prevalence has been increasing steadily 
since 1997 reaching 8.1 per 100,000 in 
2003, then declined in 2006 to 4.6/100,000 
(Figure 2.5). In Turkey, an increase in the 
prevalence of HIV in blood donations has 
been reported, rising from 2.7 per 100,000 
donations in 2002 to 7.8 in 2006. 
 
Figure 2.5: HIV prevalence in blood 
donations (per 100,000) in three central 
European countries, 1994-2006. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3 Western Europe 
In the West, HIV prevalence in blood 
donations has declined steadily since 
1990 (Figures 2.2, 2.6; Annex 2.1). Since 
2001, prevalence has been lower than 2 
per 100,000 donations in all countries 
except Greece (5.3 in 2002), Spain (6.0 in 
2005), Italy (2.7 in 2003), Israel (2.1 in 
2006) and in three major cities in Portugal 
(10.4 in 2004).  
 
 
 
 
Figure 2.6:  HIV prevalence in blood 
donations (per 100,000) in four selected 
western European countries, 1990-2006. 
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2.3 HIV prevalence among first-time 
and repeat donors, 2001-2006 
 
Information on HIV prevalence among 
first-time/candidate donors and donations 
from repeat donors was available for at 
least one year in the period 2001-2006 for 
18 countries; 14 from western, 4 from 
central and none from eastern Europe 
(Annexes 2.2, 2.3).  
 
Data for these 18 countries indicate that 
HIV prevalence is consistently up to five 
times higher in donations from first-time  
donors than from repeat donors. HIV 
prevalence in first-time or candidate 
donors was >5 per 100,000 in Finland (5.5 
in 2006), France (6.5 in 2001, decreased 
to 3.7 in 2006) and Germany (8.2 in 2003, 
decreased to 6.3 in 2006). Prevalence was 
greater than 10 per 100,000 in Poland 
(15.5 in 2001, decreased to 8.0 in 2006), 
Romania (36.8 in 2001 and 16.8 in 2006), 
Greece (18.1 in 2002) and Switzerland 
(15.6 in 2003). The rate of positive 
donations among repeat donors is more 
reflective of incidence than prevalence. It  
was <1/100,000 in all countries except 
Croatia (2.8 in 2003), France (1.1 in 2005), 
Greece (1.0 in 2002), Romania (3.1 in 
2001), Switzerland (1.6 in 2001) and also 
Luxembourg and Montenegro but, due to 
small population in those two countries, 
numbers of blood donations were 
subsequently small. 
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2.4 Discussion 
 
Increasing levels of HIV prevalence in 
blood donations have been reported from 
several countries in eastern Europe and, 
most alarmingly, in the Ukraine and 
Moldova [14]. These high levels reflect the 
intensified transmission of HIV in the 
donors’ source population. The epidemics 
of HIV among injecting drug users [15] in 
some eastern European countries (e.g. 
Estonia and the Russian Federation)  have 
been mirrored in the trends in prevalence 
of HIV positive blood donations, which 
raises important concerns regarding the 
security of the donors’ source population 
in these countries.  
 
One of the critical components of blood 
safety is the screening of blood for 
infectious agents, which became a 
mandatory key complementary measure. 
However, some countries have 
experienced difficulties in ensuring the 
proper screening for HIV of all donations, 
the implementation of quality-assured 
testing procedures and improved 
performance standards, often due to 
economic constraints [14,16,17]. Few 
cases of HIV infection transmitted through 
blood transfusion have been reported from 
eastern European countries [1,10,13,18], 
although recent outbreaks in Kazakhstan 
and Kyrgyzstan have been linked to blood 
transfusions [19,20]. 
 
Another important component of blood 
safety is the selection of donors. In many 
countries of the East, family replacement 
or paid donations [16,21,22], which are at 
increased risk of HIV infection [23], are 
often used. Furthermore, blood services 
may, paradoxically, attract some 
individuals at increased risk of HIV as 
studies have shown that the primary 
objective of a certain proportion of persons 
donating blood is to test for HIV [12]. 
Therefore, the lack of voluntary 
counselling and testing facilities in the 
East may contribute to the prevalence of 
HIV in blood donations as blood centres 
may serve as unofficial HIV testing sites 
[24,25].  
 
In contrast, countries in the West have 
adopted a strict list of donor deferral 
criteria which have been formally included 
in an European Union directive [26,27]. In 
the West, persons with high risk behaviour 
have been excluded from donating blood 
for more than two decades, including 
permanent deferral of men who have sex 
with men in many countries [28].   
 
Yet another important component of blood 
safety is the maintenance of a pool of 
regular donors, since HIV positive 
donations are much lower among them. 
This requires more resources than existing 
healthcare systems in transition can 
provide and   alternative approaches such 
as family replacement or paid donation are 
used in eastern Europe [29]. Although 
recent information on first-time/repeat 
donors is not available, this proportion is 
believed to be much lower in the eastern 
countries. 
 
Furthermore, the probability of HIV 
transmission by blood transfusion depends 
also on infected blood being donated 
during the window period. The proportion 
of HIV infected individuals who are in the 
window period will be higher in countries 
with intense on-going HIV transmission. 
Several, mostly western, European 
countries have implemented HIV nucleic 
acid testing (NAT), which decreases the 
residual risk of such HIV positive 
donations entering the blood supply [7,30]. 
However, as the residual risk in the West 
is very low, the relative gain of this 
expensive technique is of limited benefit 
[31]. On the other hand, in some countries 
of the East with high levels of HIV-infected 
blood donations and recent epidemics 
(e.g. Ukraine), such an approach could 
identify recently infected blood donations 
not yet detectable by the usual screening 
methods . Nonetheless, national 
authorities need first to ensure that good 
quality screening services are firmly 
established and that prior to the possible 
introduction of new technologies such as 
NAT, they are thoroughly evaluated for 
cost-effectiveness as well as 
transferability.  
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We have reported the number of HIV 
positive donations per 100,000, a measure 
that is dependent on the proportion of first-
time donors and on the frequency of 
donations made by repeat donors, both of 
which may vary between countries and 
over time. Recent guidelines, effective 
from July 2005 and applicable to EU 
countries only, recommend that HIV 
prevalence should be reported among 
first-time donors and HIV incidence among 
repeat donors [32]. However, many 
countries, especially in central and eastern 
Europe, have not provided this breakdown 
of data. Such information should be readily 
available as to enable national health 
authorities to evaluate the success of 
measures to encourage repeat donors, 
and thereby contribute to the safety of the 
blood supply. 
 
The control of transfusion-transmitted 
infectious diseases is a key public health 
issue. The regular reporting of HIV 
prevalence data from blood donations 
should be assured by all countries. Even if 
they are incomplete for some countries, 
these data show that improvements of 
blood safety should be implemented 
urgently in several countries in the East. 
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  Annex 2.1:     Systematic HIV antibody screening in blood banks: HIV prevalence in blood donations
(first-time or candidate donors included) by country, 2001-2006, WHO European Region
  
Geographic area     
 Country N  HIV+ N  HIV+ N  HIV+
         
 Andorra  – – – – – – – – – 
EU Austria 525,602 7 1.3 520,485 3 0.6 521,248 3 0.6
EU Belgium 705,023 0 0.0 704,946 † 0 0.0 693,271 3 0.4
EU Denmark 376,755 1 0.3 403,399 2 0.5 393,840 0 0.0
EU Finland 322,357 0 0.0 312,455 2 0.6 300,748 2 0.7
EU France 2,429,484 45 1.9 2,459,663 36 1.5 2,468,038 30 1.2
EU Germany 5,713,060 53 0.9 6,632,434 86 1.3 7,089,129 100 1.4
EU Greece 537,858 27 5.0 543,485 29 5.3 – – – 
  Iceland 14,717 0 0.0 15,598 0 0.0 – – – 
EU Ireland 147,068 1 0.7 162,502 0 0.0 151,812 2 1.3
  Israel 270,093 5 1.9 276,118 6 2.2 272,669 7 2.6
EU Italy 1,910,430 41 2.1 1,918,846 62 3.2 2,104,199 57 2.7
EU Luxembourg 21,195 1 4.7 21,282 0 0.0 21,773 0 0.0
EU Malta 16,851 0 0.0 16,173 0 0.0 16,688 0 0.0
  Monaco 1,478 ‡ 0 0.0 2,767 0 0.0 – – – 
EU Netherlands ¶ 872,000 3 0.3 927,800 8 0.9 – – – 
  Norway 199,730 0 0.0 201,607 0 0.0 209,253 0 0.0
EU Portugal || – – – – – – 105,869 12 11
  San Marino 1,062 0 0.0 784 0 0.0 883 0 0.0
EU Spain 1,505,415 76 5.0 1,506,376 73 4.8 1,621,339 88 5.4
EU Sweden ¶ 710,400 1 0.1 708,300 2 0.3 676,900 4 0.6
  Switzerland 415,151 7 1.7 415,905 2 0.5 394,495 5 1.3
EU United Kingdom 2,831,951 16 0.6 2,844,465 33 1.2 2,822,807 42 1.5
19,527,680 284 1.5 20,595,390 344 1.7 19,864,961 355 1.8
 Albania 14,000 1 7.1 – – – – – –
 Bosnia & Herzegovina 48,174 0 0.0 48,834 0 0.0 47,620 ¶ 0 0.0
EU Bulgaria 144,071 6 4.2 147,405 8 5.4 148,041 12 8.1
 Croatia 156,513 2 1.3 166,784 0 0.0 166,124 4 2.4
EU Cyprus 43,327 0 0.0 44,705 0 0.0 44,849 0 0.0
EU Czech Republic 466,774 1 0.2 510,389 1 0.2 508,127 1 0.2
EU Hungary 491,820 2 0.4 494,600 2 0.4 494,637 5 1.0
 Macedonia, F.Y.R. 50,052 0 0.0 52,145 0 0.0 53,716 0 0.0
 Montenegro 13,463 0 0.0 13,489  2 14.8  – – –  
EU Poland 932,182 28 3.0 967,090 20 2.1 1,036,010 26 2.5
EU Romania ‡ 364,732 35 9.6 365,455 15 4.1 347,227 29 8.4
 Serbia †† – – – 196,397 3 1.5 229,539 8 3.5
EU Slovakia 139,167 0 0.0 118,722 1 0.8 132,474 1 0.8
EU Slovenia  91,221 0 0.0 89,934 3 3.3 86,697 0 0.0
 Turkey 1,067,337 42 3.9 1,053,724 28 2.7 1,245,996 64 5.1
4,022,833 117 2.9 4,269,673 83 1.9 4,541,057 150 3.3
 Armenia ‡‡ 10,449 2 19.1 10,686 1 9.4 11,304 1 8.8
 Azerbaijan  12,557 0 0.0 13,944  0 0.0 17,063 1 5.9
 Belarus  347,142 3 0.9 311,672 11 3.5 328,716 14 4.3
EU Estonia  42,655 12 28.1 48,116 26 54.0 61,964 15 24.2
 Georgia ‡‡ 20,573 8 38.9 21,720 6 27.6 27,977 3 10.7
 Kazakhstan 335,407 11 3.3 338,435 23 6.8 342,836 30 8.8
  Kyrgyzstan  34,613 0 0.0 31,608 1 3.2 31,847 2 6.3
EU Latvia 83,183 4 4.8 79,909 9 11.3 81,449 12 14.7
EU Lithuania 84,440 1 1.2 82,876 0 0.0 81,784 1 1.2
 Moldova, Republic of 50,147 12 23.9 50,715 11 21.7 62,800 27 43.0
 Russian Federation 4,008,116 1,183 29.5 3,855,814 1,084 28.1 3,811,675 979 25.7
 Tajikistan – – – – – – – – –
 Turkmenistan – – – – – – – – –
 Ukraine 980,770 816 83.2 939,108 927 98.7 958,205 1,182 123.4
 Uzbekistan – – – – – – – – –
6,010,052 2,052 34.1 5,784,603 2,099 36.3 5,817,620 2,267 39.0
Total European Union 21,509,021 361 1.7 22,631,812 421 1.9 22,010,920 445 2.0
29,560,565 2,453 8.3 30,649,666 2,526 8.2 30,223,638 2,772 9.2
2001 2002
/100,000
HIV+
/100,000
HIV+
2003
HIV+
European Region
East 
Total Centre 
Total East 
Total WHO 
/100,000
Centre 
West 
Total West 
EU Countries which constitute the European Union as of 1 January 2007.
* Ref.= References, see Commentary   
† Incomplete data (95% of donations)   
‡ Blood donors (not donations)   
 || Data from regional blood centres in the three main cities (Coimbra, Lisbon and Oporto); do not represent the country as a whole
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Annex 2.1: Systematic HIV antibody screening in blood banks: HIV prevalence in blood donations
(Cont.) (first-time or candidate donors included) by country, 2001-2006, WHO European Region
    
N  HIV+ N HIV+ N HIV+ Ref.* Country 
   
– – – – – – – – –  Andorra  
514,326 7 1.4 495,663 5 1.0 492,230 7 1.4 EU Austria 
747,331 3 0.4 715,546 4 0.6 – – – EU Belgium 
391,910 3 0.8 378,750 0 0.0 375,768 3 0.8 2 EU Denmark 
285,794 0 0.0 274,870 1 0.4 278,220 2 0.7 EU Finland 
2,498,298 35 1.4 2,512,795 41 1.6 2,575,273 34 1.3 3,4 EU France 
6,370,671 77 1.2 6,258,680 87 1.4 6,456,802 80 1.2  5-7 EU Germany 
– – – – – – – – – EU Greece 
– – – – – – – – –   Iceland 
157,346 1 0.6 160,560 2 1.2 156,502 1 0.6 EU Ireland 
281,879 3 1.1 282,955 6 2.1 240,009 5 2.1   Israel 
– – – – – – – – – EU Italy 
21,017 0 0.0 21,998 0 0.0 – – – 8 EU Luxembourg 
15,292 0 0.0 14,380 0 0.0 14,806 0 0.0 EU Malta 
– – – – – – – – –   Monaco 
919,300 4 0.4 878,500 3 0.3 851,270 5 0.6 EU Netherlands ¶
214,278 0 0.0 210,717 0 0.0 215,000 1 0.5   Norway 
115,862 12 10 – – – – – – EU Portugal ||
1,078 0 0.0 – – – – – –   San Marino 
1,610,824 93 5.8 1,606,407 97 6.0 – – – EU Spain 
624,900 2 0.3 557,000 3 0.5 568,000 1 0.2 EU Sweden ¶
377,288 5 1.3 365,828 4 1.1 361,387 6 1.7   Switzerland 
2,779,863 18 0.6 – – – – – – EU United Kingdom 
17,927,257 263 1.5 14,734,649 253 1.7 12,585,267 145 1.2
– – – – – – – – –  Albania 
42,483 0 0.0 64,987 0 0.0 101,729 0 0.0  Bosnia & Herzegovina 
152,813 6 3.9 158,950 6 3.8 151,976 7 4.6 EU Bulgaria 
147,802 4 2.7 157,502 3 1.9 156,624 1 0.6  Croatia 
46,847 0 0.0 50,252 0 0.0 49,275 0 0.0 EU Cyprus 
514,523 1 0.2 524,892 1 0.2  501,877 2 0.4 9 EU Czech Republic 
505,344 3 0.6 494,351 1 0.2 467,407 1 0.2 EU Hungary 
54,758 0 0.0 – – – – – –  Macedonia, F.Y.R. 
– – –  – – –  – – –  Montenegro
1,006,639 17 1.7 986,631 31 3.1 979,686 27 2.8 EU Poland 
362,486 28 7.7 352,837 17 4.8 327,050 19 5.8 EU Romania ‡
230,812 22 9.5 225,563 7 3.1 216,902 2 0.9  Serbia ††
95,899 0 0.0 103,946 0 0.0 116,348 0 0.0 EU Slovakia 
84,684 2 2.4  85,344 2 2.3 84,882 0 0.0 EU Slovenia  
1,227,085 68 5.5 1,527,834 58 3.8 1,565,626 122 7.8  Turkey 
4,472,175 151 3.4 4,733,089 126 2.7 4,719,382 181 3.8
11,957 1 8.4 12,449 1 8.0 13,191 0 0.0 10  Armenia ‡‡
21,053 1 4.7 23,814 2 8.4 27,668 1 3.6  Azerbaijan  
320,530 15 4.7 321,664 21 6.5 318,286 20 6.3 11  Belarus  
62,040 11 17.7 54,221 7 12.9 54,448 9 16.5 12 EU Estonia  
28,156 10 35.5 31,249 7 22.4 32,394 5 15.4  Georgia ‡‡
357,814 20 5.6 358,485 30 8.4 318,460 49 15.4  Kazakhstan 
33,471 2 6.0 33,525 6 17.9 31,192 6 19.2   Kyrgyzstan  
71,264 6 8.4 56,795 13 22.9 68,076 8 11.8 EU Latvia 
85,559 1 1.2 88,423 3 3.4 65,071 3 4.6 EU Lithuania 
71,161 28 39.3 69,957 31 44.3 83,713 41 49.0  Moldova, Republic of 
3,803,488 873 23.0 3,719,740 863 23.2  3,489,235 797 22.8 13  Russian Federation 
– – –  – – –  – – –  Tajikistan 
– – –  – – –  – – –  Turkmenistan 
941,524 1,209 128.4 899,436 1,134 126.1 839,337 1,067 127.1  Ukraine 
– – –  – – – – – –  Uzbekistan 
5,808,017 2,177 37.5 5,669,758 2,118 37.4 5,341,071 2,006 37.6
20,040,832 330 1.6 16,831,791 324 1.9 14,634,967 209 1.4
28,207,449 2,591 9.2 25,137,496 2,497 9.9 22,645,720 2,332 10.3
/100,000
Geographic area
West
Total West
Centre
/100,000
Total WHO 
Total Centre
East
European Region
Total European Union 
Total East 
/100,000
HIV+
2004 2005
HIV+ HIV+
2006
 
¶ Estimate
†† No data for Kosovo   
‡‡ Due to shortage of test reagents, in some years not all blood donations were tested    
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Annex 2.2.  Systematic HIV antibody screening in blood banks: HIV prevalence in blood donations
 from first-time donors by country, 2001-2006, WHO European Region   
HIV+ HIV+ HIV+
Country N HIV+ /100,000 N HIV+ /100,000 N HIV+ /100,000
West
EU Belgium 45,849 0 0.0 41,931 0 0.0 39,005 2  
EU Denmark* 36,737 0 0.0 40,019 0 0.0 33,496 0 0.0
EU Finland 22,447 0 0.0 19,990 1 5.0 18,944 1 5.3
EU France 403,094 26 6.5 363,075 20 5.5 381,606 20 5.2
EU Germany 535,324 25 4.7 576,979 43 7.5 572,012 47 8.2
EU Greece† 102,900 18 17.5 105,000 19 18.1 – – –
EU Ireland 25,314 0 0.0 25,280 0 0.0 20,767 2 9.6
EU Luxembourg 1,803 0 0.0 758 0 0.0 699 0 0.0
EU Malta – – – 3,091 0 0.0 – – –
 Monaco 219 0 0.0 – – – – – –
EU Netherlands‡ 56,000 0 0.0 – – – – – –
EU Sweden*‡ 45,400 1 2.2 46,300 2 4.3 43,900 2 4.6
 Switzerland 31,577 1 3.2 41,772 1 2.4 19,172 3 15.6
EU United Kingdom 275,544 10 3.6 293,208 14 4.8 280,409 22 7.8
1,582,208 81 5.1 1,557,403 100 6.4 1,410,010 99 7.0
Croatia§ 11,312 0 0.0 10,347 0 0.0 18,261 2 11.0
 Montenegro 5,149 0 0.0 5,544 1 18.0 – – –
EU Poland 141,674 22 15.5 150,763 14 9.3 173,250 14 8.1
EU Romania 70,625 26 36.8 – – – – – –
228,760 48 21.0 166,654 15 9.0 191,511 16 8.4
1,762,711 128 7.3 1,666,394 113 6.8 1,564,088 110 7.0
1,810,968 129 7.1 1,724,057 115 6.7 1,601,521 115 7.2
European Union 
(EU)
Total WHO
European Region
Centre
Total Centre
Geographic area
Total West
20032001 2002
EU Countries which constitute the European Union as of 1 January 2007.
* Candidate donors: persons who apply for donating blood and have an initial HIV test before they can be registered as blood donors
† Partial data only   
‡ Estimated   
§ Data for Zagreb city and Zagreb county (25% of the population)    
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Annex 2.2.  Systematic HIV antibody screening in blood banks: HIV prevalence in blood donations
 from new or candidate do from first-time donors by country, 2001-2006, WHO European Region   
(Cont.)
  HIV+ HIV+ HIV+
N HIV+ /100,000 N HIV+ /100,000 N HIV+ /100,000 Country
West
52,422  1 1.9 54,317 0 0.0 – – – EU Belgium
35,762  1 2.8 24,296 0 0.0 29,377 0 0.0 EU Denmark*
16,858  0 0.0 16,322 0 0.0 18,108 1 5.5 EU Finland
377,175  15 4.0 374,053 18 4.8 379,928 14 3.7 EU France
519,403 25 4.8 545,330 33 6.1 511,705 32 6.3 EU Germany
–  – – – – – – – – EU Greece†
18,343  1 5.5 16,414 2 12.2 21,642 1 4.6 EU Ireland
801  0 0.0 1,802 0 0.0 – – – EU Luxembourg
–  – – – – – – – – EU Malta
–  – – – – – – – –  Monaco 
–  – – 30,173 1 3.3 – – – EU Netherlands‡
38,900  0 0.0 34,500 0 0.0 39,000 1 2.6 EU Sweden*‡
20,436  0 0.0 20,059 2 10.0 21,298 3 14.1  Switzerland
305,309  7 2.3   EU United Kingdom
1,385,409  50 3.6 1,117,266 56 5.0 1,021,058 52 5.1
     
–  – – – – – – – – Croatia§
–  – – – – – – – –  Montenegro
164,341  15 9.1 178,646 19 10.6 188,085 15 8.0 EU Poland
–  – – – – – 83,210 14 16.8 EU Romania
164,341  15 9.1 178,646 19 10.6 271,295 29 10.7
 
1,529,314 65 4.3 1,275,853 73 5.7 1,271,055 78 6.1
1,549,750  65 4.2 1,295,912 75 5.8 1,292,353 81 6.3
Total
European Union (EU)
Total WHO
European Region
Geographic area
Total West
Centre
Total Centre
200620052004
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Geographic area    HIV+   HIV+   HIV+
 Country N  HIV+ /100,000 N  HIV+ /100,000 N  HIV+ /100,000
West
EU Belgium 659,174 0 0.0 663,015 0 0.0 654,266 1 0.2
EU Denmark 340,018 1 0.3 363,380 2 0.6 360,344 0 0.0
EU Finland 299,910 0 0.0 292,465 1 0.3 281,804 1 0.4
EU France 2,026,390 19 0.9 2,096,588 16 0.8 2,086,432 10 0.5
EU Germany 5,177,736 27 0.5 6,055,455 43 0.7 6,517,117 53 0.8
EU Greece*† 205,130 2 1.0 195,500 2 1.0 – – –
EU Ireland 121,754 1 0.8 137,222 0 0.0 131,045 0 0.0
EU Luxembourg 19,392 1 5.2 20,524 0 0.0 21,074 0 0.0
EU Malta – – – 13,082 0 0.0 – – –
Monaco† 1,259 0 0.0 – – – – – –
EU Netherlands‡ 816,000 3 0.4 – – – – – –
EU Sweden 665,000 0 0.0 662,000 0 0.0 633,000 2 0.3
Switzerland 383,574 6 1.6 374,133 1 0.3 375,323 2 0.5
EU United Kingdom 2,556,407 6 0.2 2,551,257 19 0.7 2,542,398 20 0.8
13,271,744 66 0.5 13,424,621 84 0.6 13,602,803 89 0.7
Centre  
Croatia§ 56,075 0 0.0 57,621 0 0.0 142,900 4 2.8
Montenegro 8,340 0 0.0 8,788 1 11.4 – – –
EU Poland 790,508 6 0.8 816,327 6 0.7 862,760 12 1.4
EU Romania 294,107 9 3.1 – – – – – –
1,149,030 15 1.3 882,736 7 0.8 1,005,660 16 1.6
13,971,526 75 0.5 13,866,815 89 0.6 14,090,240 99 0.7
14,420,774 81 0.6 14,307,357 91 0.6 14,608,463 105 0.7
Total
European Union (EU)
2001 2002
Total West
Total Centre
2003
Annex 2.3. Systematic HIV antibody screening in blood banks: HIV prevalence in blood donations
                    from repeat donors by country, 2001-2006, WHO European Region   
Total WHO
European Region  
EU Countries which constitute the European Union as of 1 January 2007.
* Partial data only   
† Blood donors (not donations)   
‡ Estimated   
§ Data for Zagreb city and Zagreb county (25% of the population)  for 2001-2002  
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(Cont.)
  
  HIV+  HIV+  HIV+ Geographic area
N  HIV+ /100,000 N  HIV+ /100,000 N  HIV+ /100 000  Country
West
694,909 2 0.3 661,229 4 0.6 – – – EU Belgium
356,148 2 0.6 354,454 0 0.0 346,391 3 0.9 EU Denmark
268,936 0 0.0 258,548 1 0.4 260,112 1 0.4 EU Finland
2,121,123 20 0.9 2,138,742 23 1.1 2,195,345 20 0.9 EU France
5,851,268 52 0.9 5,713,350 54 0.9 5,945,097 48 0.8 EU Germany
– – – – – – – – – EU Greece*†
139,003 0 0.0 144,146 0 0.0 134,860 0 0.0 EU Ireland
20,216 0 0.0 20,196 0 0.0 – – – EU Luxembourg
– – – – – – – – – EU Malta
– – – – – – – – – Monaco†
875,944 4 0.5 848,327 2 0.2 – – – EU Netherlands‡
586,000 2 0.3 – – – – – – EU Sweden
356,852 5 1.4 345,769 2 0.6 340,298 3 0.9 Switzerland
2,474,554 11 0.4  EU United Kingdom
13,744,953 98 0.7 10,484,761 86 0.8 9,222,103 75 0.8
  Centre
– – – – – – – – – Croatia§
– – – – – – – – – Montenegro 
842,298 2 0.2 807,985 12 1.5 791,601 12 1.5 EU Poland
– – – – – – 243,840 5 2.1 EU Romania
842,298 2 0.2 807,985 12 1.5 1,035,441 17 1.6 
14,230,399 95 0.7 10,946,977 96 0.9 9,917,246 89 0.9
 
    
14,587,251 100 0.7 11,292,746 98 0.9 10,257,544 92 0.9
20062004
European Region
 Annex 2.3. Systematic HIV antibody screening in blood banks: HIV prevalence in blood donations
                      from repeat donors by country, 2001-2006, WHO European Region    
Total West
Total Centre
Total
European Union (EU)
Total WHO
2005
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Technical note 
 
All 53 countries of the WHO European 
Region participate in the HIV/AIDS 
surveillance activities coordinated by 
EuroHIV (European Centre for the 
Epidemiological Monitoring of HIV/AIDS).  
A single institution in each country (see 
back cover) reports national data to 
EuroHIV and is responsible for the quality 
of the data provided. 
 
 
Reporting of HIV infection and AIDS  
 
Data collection and management 
Data on HIV and AIDS cases are reported 
to EuroHIV in a standard format. Individual 
data are reported without personal 
identifiers and elimination of duplicate 
reports between countries is therefore not 
possible.  Since linkage between HIV and 
AIDS databases is not possible in all 
countries, two separate databases are 
maintained at European level (see Report 
no. 75 [1]). New complete databases are 
provided at each update to allow validation 
and inclusion of follow-up data on 
previously reported cases. 
 
For details on AIDS reporting, see Report 
no. 75 [1]. 
 
HIV infection 
Reporting of cases of newly diagnosed 
HIV infection started at different times [1] 
in European countries and is now 
implemented in most of them (Annex 1. 1).   
 
Anonymous, individual data on all reported 
cases are sent annually to EuroHIV, 
according to a standard data file 
specification, by countries able to provide 
individual data.  After validation, these 
data are merged into the European HIV 
Infection Data Set (EHIDS). From other 
countries, aggregate data (by sex, age 
group, transmission group and half-year of 
report) on new cases reported are 
provided annually, with no updating of 
previously reported data. 
 
 
 
 
HIV infection case definition 
A case of HIV infection is defined as an 
individual with HIV infection confirmed 
according to country definitions and 
requirements, diagnosed at any clinical 
stage including AIDS, and not previously 
reported in that country.  For children aged 
under 18 months at diagnosis, at least one 
direct detection HIV test (non-antibody 
based) is also required.  Adult/adolescent 
cases are defined as those aged 13 years 
and over, and paediatric cases as those 
under 13 years. 
 
Reported HIV cases represent mostly new 
diagnoses; only a minority of reported 
cases has been diagnosed (but not 
reported) previously and, when this is the 
case, the previous diagnosis was 
frequently made anonymously or in 
another country. 
 
Transmission groups 
For surveillance purposes, cases 
attributable to more than one mode of 
transmission are counted once only in a 
hierarchy which is intended to correspond 
to the most probable route of transmission.  
This hierarchy varies slightly within the 
WHO European Region.  Likewise, relative 
risks of infection among different 
transmission groups vary between 
countries.  Furthermore, the definition for 
heterosexual transmission varies slightly 
between countries. 
 
Patterns of HIV diagnosis and reporting 
The proportion of newly diagnosed HIV 
cases infected in previous years and the 
overall proportion of all prevalent HIV 
infections that have been diagnosed are 
unknown, and are believed to differ widely 
between countries and between sub-
populations within countries. They are 
heavily dependent on HIV testing patterns 
among high risk populations, access to 
voluntary counselling and testing, and 
access to care, all of which vary by 
country.  
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HIV prevalence assessment in specific 
populations 
 
HIV prevalence data from the participating 
countries are updated regularly and 
compiled in the European HIV Prevalence 
Database.  This database contains 
aggregate data on HIV prevalence in 
various populations (e.g. injecting drug 
users, pregnant women) in the countries of 
the WHO European Region.  Data 
included must comply with specific quality 
criteria and availability of information on 
the study methods (e.g. representativity of 
the study population, minimum sample 
size, availability of data by periods of 1 
year or less).  
 
In addition to classical epidemiological 
surveys where testing may be unlinked 
and anonymous, prevalence may be 
assessed through data obtained from HIV 
testing programmes which, in turn, may be 
voluntary or mandatory (e.g. testing of 
blood donations), or through self-reported 
HIV serostatus (e.g. among participants in 
behavioural surveys).  Studies are 
conducted nationally, locally or both; some 
are continuous (notably those based on 
testing programmes) while others are 
periodical or occasional. 
 
For each study, the following information is 
recorded: characteristics of the population 
tested (target population, geographic 
coverage, recruitment site); sampling and 
testing methods; and numbers of subjects 
tested (or, for self-reported data, ever-
tested) and found (or reported) to be HIV 
positive.  For studies which have been 
published, bibliographical references are 
also included in the database. 
 
 
Data presentation 
 
The data in the report are provisional 
because previously reported data are 
subject to regular update (e.g. detection 
and deletion of duplicate cases, inclusion 
of new information about already reported 
cases). 
 
Data are presented by geographic area 
(see below); sub-totals are also shown for 
the 27 countries which constitute the 
European Union as of 1 January 2007 
(population 492 million). 
 
Country population denominators used to 
calculate rates are based on data from the 
nited Nations Population Division [2]. U 
Geographic areas 
Based on geopolitical and epidemiological 
considerations, the 53 countries have 
been grouped into three geographic areas: 
• West: 23 countries with a total 
population of 408 million: Andorra, 
Austria∗, Belgium*, Denmark*, Finland*, 
France*, Germany*, Greece*, Iceland, 
Ireland*, Israel, Italy*, Luxembourg*, 
Malta*, Monaco, Netherlands*, Norway, 
Portugal*, San Marino, Spain*, 
Sweden*, Switzerland, United 
Kingdom*;  
• East: the 15 countries of the former 
Soviet Union with a total population of 
284 million: Armenia, Azerbaijan, 
Belarus, Estonia*, Georgia, 
Kazakhstan, Kyrgyzstan, Latvia*, 
Lithuania*, Republic of Moldova, 
Russian Federation, Tajikistan, 
Turkmenistan, Ukraine, Uzbekistan; 
• Centre: the 15 remaining countries of 
the WHO European Region with a total 
population of 192 million: Albania, 
Bosnia and Herzegovina, Bulgaria*, 
Croatia, Cyprus*, Czech Republic*, 
Hungary*, Former Yugoslav Republic of 
Macedonia, Montenegro, Poland*, 
Romania*, Serbia, Slovakia*, Slovenia*, 
Turkey. 
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∗ Countries which constitute the European 
Union as of 1 January 2007 
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Albania Institute of Public Health, Tirana
Andorra Ministry of Health and Welfare, Andorra la Vella
Armenia National Centre for AIDS Prevention, Yerevan
Austria Federal Ministry for Health and Women, Vienna
Azerbaijan Azerbaijan Centre for AIDS Prevention, Baku
Belarus Republican Centre of Hygiene, Epidemiology and Public Health, Minsk
Belgium Scientific Institute of Public Health, Brussels
Bosnia & Herzegovina Federal Ministry of Health, Sarajevo
 National Public Health Institute of Republic Srpska, Banja Luka
Bulgaria Ministry of Health, Sofia
Croatia Croatian National Institute of Public Health, Zagreb
Cyprus Ministry of Health, Nicosia
Czech Republic National Institute of Public Health, Prague
Denmark Statens Serum Institute, Copenhagen
Estonia Health Protection Inspectorate, Tallinn
Finland National Public Health Institute, Helsinki
France Institut de Veille Sanitaire, Saint-Maurice
Georgia Georgian AIDS and Clinical Immunology Research Centre, Tbilisi
Germany Robert Koch-Institut, Berlin
Greece Hellenic Centre for Disease Prevention & Control, Athens
Hungary National Centre for Epidemiology, Budapest
Iceland Directorate of Public Health, Reykjavik
Ireland Health Protection Surveillance Centre, Dublin
Israel Ministry of Health, Jerusalem
Italy Istituto Superiore di Sanità, Rome
Kazakhstan Centre for AIDS Prevention and Control, Almaty
Kyrgyzstan National Centre for AIDS Prevention and Control, Bishkek
Latvia Public Health Agency – AIDS and STI Prevention Centre, Riga
Lithuania Lithuanian AIDS Centre, Vilnius
Luxembourg Direction de la Santé, Luxembourg
Macedonia, Former Yugoslav Republic of Republic Institute for Health Protection, Skopje
Malta Department of Public Health, Msida
Moldova, Republic of National Centre for AIDS Prevention and Control, Chisinau
Monaco Direction de l'Action Sanitaire et Sociale, Monaco
Montenegro  Institute of Public Health of Montenegro, Podgorica
Netherlands National Institute for Public Health & the Environment, Bilthoven
Norway Norwegian Institute of Public Health, Oslo
Poland National Institute of Hygiene, Warsaw
Portugal National Institute of Health Dr Ricardo Jorge, Lisbon
Romania Matei Bals Institute of Infectious Diseases, Bucharest
Russian Federation Russian Federal AIDS Centre, Moscow
San Marino Authority Sanitaria e Socio-Sanitaria, San Marino
Serbia Institute of Public Health of Serbia, Belgrade
Slovak Republic State Public Health Institute, Bratislava
Slovenia Institute of Public Health, Ljubljana
Spain Instituto de Salud "Carlos III", Madrid
Sweden Swedish Institute for Infectious Disease Control, Solna
Switzerland Swiss Federal Office of Public Health, Bern
Tajikistan National AIDS Centre, Dushanbe
Turkey Ministry of Health, Ankara
Turkmenistan National AIDS Prevention Centre, Ashgabat
Ukraine Ukrainian AIDS Centre, Kiev
United Kingdom Health Protection Agency, London
 Health Protection Scotland, Glasgow
Uzbekistan Republican Centre for AIDS Prevention and Control, Tashkent
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